Skip to content

bimatoprost in vitiligo

A comparative study of combination therapy using fractional co2 laser and topical Bimatoprost versus fractional co2 laser and Tacrolimus ointment in the treatment of non-segmental vitiligo

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250726066639N1
Enrollment
33
Registered
2025-08-19
Start date
2025-08-21
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo. Vitiligo

Interventions

Intervention 1: intervention:For each patient, two symmetrical lesions on opposite sides of the body were selected. Lesion A was treated with fractional CO2 laser once a month for a total of three ses

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor
Sinadarou Pharmaceutical Company
Collaborator

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: Individuals over 12 years of age with stable non-segmental vitiligo Individuals with less than 20% body surface area involvement Involvement of areas other than the face and neck Presence of at least one vitiligo lesion on each side of the body, with approximately symmetrical location and appearance

Exclusion criteria

Exclusion criteria: Use of conventional vitiligo treatments, such as topical or systemic medications and phototherapy, within the past 3 months. Presence of other Koebner-positive skin diseases. Active disease within the past 6 months, defined as the development of new lesions or progression of existing ones. Pregnancy or breastfeeding. Hypersensitivity to the drug components. Presence of wounds or infections at the procedure site. History of keloid or hypertrophic scar.

Design outcomes

Primary

MeasureTime frame
Extent of the vitiligo lesion. Timepoint: 0,1,2,3,5 month. Method of measurement: Vitiligo Area Scoring Index score.;Percentage of skin repigmentation. Timepoint: At 90 days after study initiation. Method of measurement: Quartile grading scale.

Secondary

MeasureTime frame
Patient satisfaction score. Timepoint: 0,1,2,3,5 month. Method of measurement: Patient satisfaction score based on treatment response (ranging from 1 to 4): 1 = Not satisfied, 2 = Moderately satisfied, 3 = Satisfied, 4 = Highly satisfied.;Side effects. Timepoint: 1,2,3,5 month. Method of measurement: Investigator’s observations and patient-reported outcomes.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMotahareh Babazadeh Dezfouli

Ahvaz University of Medical Sciences

motaharehbabazadeh@gmail.com008 061 32921873

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026